Literature DB >> 32130618

LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis.

Lixia Yao1,2, Bolun Zhou3, Ling You1, Haijuan Hu1, Ruiqin Xie4.   

Abstract

Atrial fibrillation (AF) is a commonly encountered heart arrhythmia and a risk factor for cardiovascular system. The purpose of the present study was to explore the role of long non-coding RNA myocardial infarction-associated transcript (MIAT) in AF and AF-induced myocardial fibrosis and the possible mechanisms involved in this process. We successfully induced an AF rat model. Expression of MIAT presented a dramatic increase, while microRNA (miR)-133a-3p presented a dramatic decrease in atrium tissues of rats with AF induction. In addition, we also found that MIAT was highly expressed and miR-133a-3p was significantly reduced in peripheral blood leukocyte of AF patients. For biological function exploration of MIAT/miR-133a-3p axis, MIAT was knocked down using small hairpin RNA (shRNA) lentivirus injection and the rescue experiments were performed simultaneously by inhibiting miR-133a-3p using anti-miR-133a-3p lentivirus injection in rats with AF. MIAT downregulation significantly alleviated AF, increased atrial effective refractory period (AERP), and reduced the duration of AF as well as cardiomyocytes apoptosis. Whereas these effects of MIAT downregulation on AF were reversed by anti-miR-133a-3p administration. Luciferase reporter revealed that miR-133a-3p was directly regulated by MIAT. Moreover, MIAT knockdown effectively reduced AF-induced atrial fibrosis by detecting reduced collagen in the right atria and inhibited expression of fibrosis-related gene expression of collagen I, collagen III, connective tissue growth factor (CTGF) and transforming growth factor-β1 (TGF-β1) in rats with AF, these findings were in contrast with the findings for rats with inhibition of miR-133a-3p. In conclusion, our study demonstrated the role of MIAT downregulation in alleviating AF and AF-induced myocardial fibrosis, and the functional regulatory pathway of MIAT targeting miR-133a-3p.

Entities:  

Keywords:  Atrial fibrillation; MicroRNA-133a-3p; Myocardial fibrosis; Myocardial infarction-associated transcript; Rat

Mesh:

Substances:

Year:  2020        PMID: 32130618     DOI: 10.1007/s11033-020-05347-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  33 in total

Review 1.  Interplay of chromatin modifications and non-coding RNAs in the heart.

Authors:  Prabhu Mathiyalagan; Samuel T Keating; Xiao-Jun Du; Assam El-Osta
Journal:  Epigenetics       Date:  2013-10-10       Impact factor: 4.528

2.  Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.

Authors:  Andre Feldman; Dalmo Antonio Ribeiro Moreira; Carlos Gun; Hui-Tzu Lin Wang; Mario Hiroyuki Hirata; Juliana de Freitas Germano; Gabriela Guimarães Sousa Leite; Pedro Farsky
Journal:  Ann Hum Genet       Date:  2017-05       Impact factor: 1.670

Review 3.  [Electrophysiologic mechanisms of atrial rhythm disorders. I. Atrial fibrillation].

Authors:  B Stancák
Journal:  Vnitr Lek       Date:  1998-08

4.  Effect of heparin on polymerase chain reaction.

Authors:  J Satsangi; D P Jewell; K Welsh; M Bunce; J I Bell
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

5.  A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (KCa 2) channels.

Authors:  Rafel Simó-Vicens; Jeppe E Kirchhoff; Bernardo Dolce; Lea Abildgaard; Tobias Speerschneider; Ulrik S Sørensen; Morten Grunnet; Jonas G Diness; Bo H Bentzen
Journal:  Br J Pharmacol       Date:  2017-10-22       Impact factor: 8.739

6.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

Review 7.  Mechanisms of persistent atrial fibrillation.

Authors:  José Jalife
Journal:  Curr Opin Cardiol       Date:  2014-01       Impact factor: 2.161

8.  Long noncoding RNAs in patients with acute myocardial infarction.

Authors:  Mélanie Vausort; Daniel R Wagner; Yvan Devaux
Journal:  Circ Res       Date:  2014-07-17       Impact factor: 17.367

9.  Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart.

Authors:  Lars B van Middendorp; Marion Kuiper; Chantal Munts; Philippe Wouters; Jos G Maessen; Frans A van Nieuwenhoven; Frits W Prinzen
Journal:  ESC Heart Fail       Date:  2017-04-03

10.  Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease.

Authors:  Dorothee Kaudewitz; Regent Lee; Peter Willeit; Reuben McGregor; Hugh S Markus; Stefan Kiechl; Anna Zampetaki; Robert F Storey; Keith M Channon; Manuel Mayr
Journal:  Thromb Haemost       Date:  2013-06-27       Impact factor: 5.249

View more
  16 in total

1.  MIAT, a potent CVD-promoting lncRNA.

Authors:  Chao Yang; Yong Zhang; Baofeng Yang
Journal:  Cell Mol Life Sci       Date:  2021-12-18       Impact factor: 9.261

Review 2.  Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials.

Authors:  Yuncong Shi; Huanji Zhang; Suli Huang; Li Yin; Feng Wang; Pei Luo; Hui Huang
Journal:  Signal Transduct Target Ther       Date:  2022-06-25

Review 3.  Leveraging Extracellular Non-coding RNAs to Diagnose and Treat Heart Diseases.

Authors:  Zhenyi Zhao; Ningning Guo; Weixin Chen; Zhihua Wang
Journal:  J Cardiovasc Transl Res       Date:  2022-04-13       Impact factor: 3.216

4.  Serum extracellular vesicles containing MIAT induces atrial fibrosis, inflammation and oxidative stress to promote atrial remodeling and atrial fibrillation via blockade of miR-485-5p-mediated CXCL10 inhibition.

Authors:  Yingwei Chen; Xiaojie Chen; Haiyu Li; Yunpeng Li; Dong Cheng; Yi Tang; Haiqiang Sang
Journal:  Clin Transl Med       Date:  2021-08

Review 5.  Research Progress of LncRNAs in Atrial Fibrillation.

Authors:  Wenhui Wang; Bei Tian; Zhongping Ning; Xinming Li
Journal:  Mol Biotechnol       Date:  2022-02-02       Impact factor: 2.695

Review 6.  Transforming Growth Factor-β and Long Non-coding RNA in Renal Inflammation and Fibrosis.

Authors:  Yue-Yu Gu; Jing-Yun Dou; Xiao-Ru Huang; Xu-Sheng Liu; Hui-Yao Lan
Journal:  Front Physiol       Date:  2021-05-13       Impact factor: 4.566

7.  LncRNA XR_596701 protects H9c2 cells against intermittent hypoxia-induced injury through regulation of the miR-344b-5p/FAIM3 axis.

Authors:  Qingshi Chen; Guofu Lin; Lanlan Lin; Jiefeng Huang; Lida Chen; Ningfang Lian; Mengxue Chen; Aiming Zeng; Qichang Lin
Journal:  Cell Death Discov       Date:  2022-01-28

8.  Identifying ceRNA Networks Associated With the Susceptibility and Persistence of Atrial Fibrillation Through Weighted Gene Co-Expression Network Analysis.

Authors:  Yaozhong Liu; Na Liu; Fan Bai; Qiming Liu
Journal:  Front Genet       Date:  2021-06-23       Impact factor: 4.599

Review 9.  Long Non-Coding RNAs in Atrial Fibrillation: Pluripotent Stem Cell-Derived Cardiomyocytes as a Model System.

Authors:  Emre Bektik; Douglas B Cowan; Da-Zhi Wang
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 10.  Genetics and Epigenetics of Atrial Fibrillation.

Authors:  Estefanía Lozano-Velasco; Diego Franco; Amelia Aranega; Houria Daimi
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.